PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
64.30
-0.61 (-0.94%)
Nov 12, 2026, 11:12 AM EST - Market open
PTC Therapeutics Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, PTC Therapeutics stock has a consensus rating of "Buy" and an average price target of $100.47. The average 1-year stock price forecast is 56.25% higher than the current stock price, while the lowest is $62 (-3.58%) and the highest is $137 (+113.06%).
Price Target: $100.47 (+56.25%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for PTC Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 8 | 9 | 9 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 2 | 2 | 2 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Total | 14 | 14 | 14 | 14 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Buy Reiterates $91 → $92 | Buy | Reiterates | $91 → $92 | +43.08% | Nov 2, 2026 |
| Citi | Citi | Buy Maintains $108 → $109 | Buy | Maintains | $108 → $109 | +69.52% | Nov 2, 2026 |
| Barclays | Barclays | Buy Maintains $122 | Buy | Maintains | $122 | +89.74% | Nov 2, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Oct 30, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $137 | Buy | Maintains | $137 | +113.06% | Oct 30, 2026 |
Financial Forecast
Revenue This Year
1.32B
from 1.73B
Decreased by -23.74%
Revenue Next Year
1.43B
from 1.32B
Increased by 8.29%
EPS This Year
0.94
from 7.62
Decreased by -87.73%
EPS Next Year
2.43
from 0.94
Increased by 159.89%
EPS and Forward PE are based on non-GAAP adjusted numbers.